Biomanufacturing property-tunable biopolymers from renewable resources
Advanced biomanufacturing process for synthesizing tunable polyhydroxyalkanoates (PHAs) from corn starch and lignocellulose, offering biodegradable and biocompatible solutions for packaging and medical applications.
Overview
This solution leverages advanced biomanufacturing techniques to produce polyhydroxyalkanoates (PHAs), a type of biopolymer, from renewable resources such as corn starch and lignocellulose. PHAs stand out due to their tunable thermal and mechanical properties, which can be adjusted by modifying the monomer composition and ratios. This makes them highly suitable for both packaging and medical applications, offering a biodegradable and biocompatible alternative to conventional petroleum-derived plastics.
Technical specifications
Key features:
- Uses corn starch and lignocellulose hydrolysates as cost-effective raw materials.
- Employs systems metabolic engineering and synthetic biology to enhance PHAs titer, yield, and rate.
- Modulates PHAs monomer composition for tailored thermal and mechanical properties.
- Utilizes 13C-Metabolic Flux Analysis and genome-scale modeling for iterative strain development.
- Capable of producing PHAs with varied chain lengths and properties, suited for applications like injection molding.
Technology readiness level
The current stage of development is at Technology Readiness Level 3. The process involves initial proof-of-concept studies with ongoing efforts to optimize microbial strains and production processes for enhanced performance and scalability.
About University of Minnesota
The University of Minnesota is a flagship, comprehensive public research university spanning multiple campuses, with a large research enterprise and clinical integration. Industry engages through co-located labs on the Twin Cities campuses, access to an academic health system for clinical translation, and pilot and field-testing facilities that speed scale-up. A statewide extension network and outreach centers provide real-world sites and data partnerships across Minnesota, while proximity to a dense medtech and Fortune 500 corridor enables frequent collaboration. Research is supported by competitive federal funding, including NIH, NSF, DOE, USDA, and DoD. A dedicated technology transfer office manages IP, licensing, sponsored research agreements, and startup incubation to speed commercialization.
delivered to your inbox.